Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia

NCT02954471 ·Status: COMPLETED

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

NCT05149014 ·Status: COMPLETED

An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants

NCT02535026 ·Status: COMPLETED

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

NCT05367739 ·Status: COMPLETED

A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark

NCT05452798 ·Status: COMPLETED

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 ·Status: RECRUITING

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

NCT04874025 ·Status: COMPLETED

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 ·Status: RECRUITING

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

NCT01525589 ·Status: COMPLETED ·Phase: PHASE2

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

NCT05769751 ·Status: COMPLETED

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

NCT00371345 ·Status: COMPLETED ·Phase: PHASE2

A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

NCT05478590 ·Status: COMPLETED

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

NCT05155566 ·Status: COMPLETED

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

NCT02491983 ·Status: COMPLETED ·Phase: PHASE2

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

NCT05599334 ·Status: COMPLETED

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

NCT07002177 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898 ·Status: COMPLETED

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

NCT05792410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

NCT07076680 ·Status: WITHDRAWN

A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

NCT02613208 ·Status: COMPLETED

A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

NCT06705504 ·Status: COMPLETED

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

NCT05697146 ·Status: ACTIVE_NOT_RECRUITING

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT06805812 ·Status: RECRUITING

This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer.

NCT07309887 ·Status: NOT_YET_RECRUITING

Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe

NCT04109261 ·Status: COMPLETED